US FDA approves GSK's Fluarix for paediatric use
This article was originally published in Scrip
Executive Summary
The US FDA has approved GlaxoSmithKline's seasonal influenza vaccine Fluarix for children aged three to 17 years. The vaccine, which contains inactivated influenza A and B viruses, was previously approved for use in adults aged 18 years and older.